These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 32097671)

  • 1. Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer.
    Jin KT; Wang SB; Ying XJ; Lan HR; Lv JQ; Zhang LH; Motallebnezhad M; Mou XZ
    Immunol Lett; 2020 May; 221():61-71. PubMed ID: 32097671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitor associated neurotoxicity: Much more than meets the eye.
    Raibagkar P
    Immunol Lett; 2020 May; 221():72-74. PubMed ID: 32092358
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated adverse events in the digestive system.
    Li Y; Kang X; Wang H; Guo X; Zhou J; Duan L; Si X; Zhang L; Liu X; Qian J; Zhang L
    Thorac Cancer; 2020 Apr; 11(4):829-834. PubMed ID: 32107847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors.
    Vardhana S; Cicero K; Velez MJ; Moskowitz CH
    Oncologist; 2019 Jan; 24(1):86-95. PubMed ID: 30082490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections.
    Lu M; Zhang L; Li Y; Wang H; Guo X; Zhou J; Duan L; Si X; Xu Y; Zhang L
    Thorac Cancer; 2020 Mar; 11(3):805-809. PubMed ID: 31970940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of immune checkpoint inhibitor-related rheumatic adverse events.
    Zhou J; Wang H; Guo X; Wang Q; Duan L; Si X; Zhang L; Liu X; Li Y; Zhang W; Zhang L
    Thorac Cancer; 2020 Jan; 11(1):198-202. PubMed ID: 31762209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management.
    Zhang Q; Tang L; Zhou Y; He W; Li W
    Front Immunol; 2021; 12():663986. PubMed ID: 34122422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse effects of immuno-oncology drugs-Awareness, diagnosis, and management: A literature review of immune-mediated adverse events.
    Aggarwal S
    Indian J Cancer; 2019 Nov; 56(Supplement):S10-S22. PubMed ID: 31793438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors.
    Xiao Y; Zeng L; Shen Q; Zhou Z; Mao Z; Wang Q; Zhang X; Li Y; Yao W
    J Immunol Res; 2020; 2020():2640273. PubMed ID: 32832568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.
    Baraibar I; Melero I; Ponz-Sarvise M; Castanon E
    Drug Saf; 2019 Feb; 42(2):281-294. PubMed ID: 30649742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities.
    Xu Y; Fu Y; Zhu B; Wang J; Zhang B
    Front Immunol; 2020; 11():2023. PubMed ID: 33123120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events.
    Davies M; Duffield EA
    Immunotargets Ther; 2017; 6():51-71. PubMed ID: 28894725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous adverse effects of the immune checkpoint inhibitors.
    Collins LK; Chapman MS; Carter JB; Samie FH
    Curr Probl Cancer; 2017; 41(2):125-128. PubMed ID: 28190531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
    Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
    Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors.
    Suarez-Almazor ME; Pundole X; Abdel-Wahab N; Johnson DB; Gupta D; Glezerman I; Cooksley T; Anderson R; Blidner A; Choi J; Dougan M; Ginex P; Girotra M; Shannon VR; Rapoport BL
    Support Care Cancer; 2020 Dec; 28(12):6159-6173. PubMed ID: 32856212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience.
    Vitale G; Lamberti G; Comito F; Di Nunno V; Massari F; Morelli MC; Ardizzoni A; Gelsomino F
    Expert Opin Biol Ther; 2020 Sep; 20(9):1047-1059. PubMed ID: 32425081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
    Yao L; Jia G; Lu L; Bao Y; Ma W
    Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
    Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
    J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.
    Chen CH; Yu HS; Yu S
    Curr Oncol; 2022 Apr; 29(4):2871-2886. PubMed ID: 35448208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.